The CCSG senior leadership comprises The University of Texas MD Anderson Cancer Center president and principal investigator, Dr. Peter Pisters; vice president for Translational Research and deputy director, Dr. Robert Bast; chief scientific officer ad interim, Dr. Giulio Draetta; associate director, Cancer Prevention and Population Sciences, Dr. Ernie Hawk; associate director, Clinical and Interdisciplinary Research, Dr. George Wilding; associate director, Clinical Research Administration, Dr. Aman Buzdar; associate director, Cancer Health Disparities and Community Outreach, Dr. Lorna McNeill; associate director, Career Enhancement, Dr. Michelle Barton; and associate director, CCSG Administration, Dr. Alan McClelland. As president of MD Anderson, Dr. Pisters has authority over all aspects of the institution, providing vision and ultimate oversight for all clinical, research, education, and prevention activities. The CCSG Executive Committee includes all senior CCSG leaders and is chaired by Dr. Pisters, ensuring alignment between the overall institutional leadership structure and that of the CCSG. MD Anderson uses several external and internal review mechanisms for planning and evaluation to develop and improve the cancer center. Funding from the CCSG supports an External Advisory Board (EAB), consisting of 34 distinguished scientific advisors that meets annually to provide advice to Dr. Pisters, CCSG senior leadership, CCSG program leaders, and CCSG shared resource directors. The EAB reviews research programs and shared resources to 1) evaluate their productivity, excellence, and alignment with institutional goals; 2) identify gaps in scientific expertise or capabilities and suggest options for closing these gaps; 3) consider new programs or restructuring of existing programs; 4) assist in recruiting outstanding faculty to the institution; and 5) evaluate the extent of collaboration among basic scientists, translational/clinical scientists, and population-based investigators, recommending actions to enhance interactivity among these 3 groups. Mechanisms for internal review of research programs, shared resources, and research planning include program retreats; clinical research protocol and concept reviews; presentations by program leaders and shared resource directors to the CCSG Executive Committee and to other leadership groups, including the Community of Chairs meeting of all department chairs; and meetings of center leadership with program leaders. Surveys, focus groups, and user committees have also reviewed each shared resource during the current grant period. As a prelude to updating MD Anderson's Strategic Plan, several Operational Priority task forces have been charged with defining and implementing specific near-term actions of immediate importance to the MD Anderson mission. Although the operational priorities do not represent a strategic plan, the focus on these priorities has established a foundation on which the strategic plan will be developed over the coming year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-43
Application #
9794689
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Boddu, Prajwal; Masarova, Lucia; Verstovsek, Srdan et al. (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97:109-121
Casasent, Anna K; Schalck, Aislyn; Gao, Ruli et al. (2018) Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing. Cell 172:205-217.e12
Noh, Hyangsoon; Zhao, Qingnan; Yan, Jun et al. (2018) Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185
Hutcheson, Katherine A; Barrow, Martha P; Plowman, Emily K et al. (2018) Expiratory muscle strength training for radiation-associated aspiration after head and neck cancer: A case series. Laryngoscope 128:1044-1051
Zhao, Jun; Xiao, Zhilan; Li, Tingting et al. (2018) Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. ACS Nano 12:9881-9893
Akhtari, Mani; Milgrom, Sarah A; Pinnix, Chelsea C et al. (2018) Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 131:84-94
Barua, Souptik; Solis, Luisa; Parra, Edwin Roger et al. (2018) A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. Cancer Inform 17:1176935118782880
Ma, Junsheng; Chan, Wenyaw; Tilley, Barbara C (2018) Continuous time Markov chain approaches for analyzing transtheoretical models of health behavioral change: A case study and comparison of model estimations. Stat Methods Med Res 27:593-607
Bayraktar, Recep; Ivan, Cristina; Bayraktar, Emine et al. (2018) Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clin Cancer Res 24:4225-4241
Parra, Edwin R; Villalobos, Pamela; Mino, Barbara et al. (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93

Showing the most recent 10 out of 12418 publications